Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple‐Negative Breast Cancer
Advanced Science · 2024
DOI: 10.1002/advs.202305035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Changxin Zhong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Elongation Factor 2 Kinase. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Hunan Provincial Innovation Foundation for Postgraduate.
Abstract (Originalsprache)
Dysregulated eEF2K expression is implicated in the pathogenesis of many human cancers, including triple‐negative breast cancer (TNBC), making it a plausible therapeutic target. However, specific eEF2K inhibitors with potent anti‐cancer activity have not been available so far. Targeted protein degradation has emerged as a new strategy for drug discovery. In this study, a novel small molecule chemical is designed and synthesized, named as compound C1 , which shows potent activity in degrading eEF2K. C1 selectively binds to F8, L10, R144, C146, E229, and Y236 of the eEF2K protein and promotes its proteasomal degradation by increasing the interaction between eEF2K and the ubiquitin E3 ligase βTRCP in the form of molecular glue. C1 significantly inhibits the proliferation and metastasis of TNBC cells both in vitro and in vivo and in TNBC patient‐derived organoids, and these antitumor effects are attributed to the degradation of eEF2K by C1 . Additionally, combination treatment of C1 with paclitaxel, a commonly used chemotherapeutic drug, exhibits synergistic anti‐tumor effects against TNBC. This study not only generates a powerful research tool to investigate the therapeutic potential of targeting eEF2K, but also provides a promising lead compound for developing novel drugs for the treatment of TNBC and other cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
- Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, 410011, China.
- Department of Medicinal Chemistry, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, 215123, China.
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410011, China.
- Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
- Department of Cancer Biology and Toxicology, Department of Pharmacology, College of Medicine and Markey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.
ORCID-Profile: Yan Cheng
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- Hunan Provincial Innovation Foundation for Postgraduate
- Fundamental Research Funds for the Central Universities of Central South University
- Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutes
Zitieren
APA
Zhong, C., Zhu, R., Jiang, T., Tian, S., Zhao, X., Wan, X., Jiang, S., Chen, Z., Gong, R., He, L., Yang, J. M., Ye, N., & Cheng, Y. (2024). Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple‐Negative Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202305035
Vancouver
Zhong C, Zhu R, Jiang T, Tian S, Zhao X, Wan X, et al. Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple‐Negative Breast Cancer. Advanced Science. 2024. doi:10.1002/advs.202305035
BibTeX
@article{Zhong2024,
author = {Zhong, Changxin and Zhu, Rongfeng and Jiang, Ting and Tian, Sheng and Zhao, Xiaobao and Wan, Xiaoya and Jiang, Shilong and Chen, Zonglin and Gong, Rong and He, Linhao and Yang, Jin-Ming and Ye, Na and Cheng, Yan},
title = {Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple‐Negative Breast Cancer},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202305035}
}
EUVIMED